Core Scientific (CORZ) EBT (2020 - 2026)

Core Scientific has disclosed EBT across 7 years of filings, most recently posting -$346.6 million for Q1 2026.

• EBT for Q1 2026 came in at -$346.6 million, down 160.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 13.03% YoY), and the FY2025 annual result was -$288.0 million, up 79.96% from the prior year.
• EBT came in at -$346.6 million for Q1 2026 at Core Scientific, down from $216.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $576.5 million in Q1 2025 to a low of -$936.6 million in Q2 2025.
• The 5-year median for EBT is -$290.8 million (2024), against an average of -$263.6 million.
• Across the five-year window, EBT tumbled 25965.69% in 2022 and soared 74359.51% in 2024, its largest moves.
• Core Scientific's EBT stood at -$456.3 million in 2022, then jumped by 57.19% to -$195.4 million in 2023, then tumbled by 48.84% to -$290.8 million in 2024, then jumped by 174.3% to $216.1 million in 2025, then tumbled by 260.42% to -$346.6 million in 2026.
• The last three EBT figures came in at -$346.6 million (Q1 2026), $216.1 million (Q4 2025), and -$143.9 million (Q3 2025), per Business Quant data.